| Literature DB >> 30196836 |
Divyanshu Dubey1, Naga Kothapalli2, Andrew McKeon3, Eoin P Flanagan3, Vanda A Lennon3, Christopher J Klein3, Jeffrey W Britton2, Elson So2, Bradley F Boeve2, Jan-Mendelt Tillema2, Reza Sadjadi4, Sean J Pittock3.
Abstract
Recognition of autoimmunity as a cause of encephalopathy has increased. Recent studies have validated the use of Antibody-Prevalence-in-Epilepsy (APE) and Responsive-to-immunotherapy-in-Epilepsy (RITE) scores in the evaluation and management of autoimmune-epilepsy. We aim to assess the utility of these models for patients with cognitive dysfunction. Among the evaluated patients, 17% had antibodies universally associated with autoimmune-encephalopathy. NMDA-R-IgG and LGI1-IgG were the most common antibody specificities. Antibody-Prevalence-in-Epilepsy-and-Encephalopathy (APE2) score ≥ 4 was 99% sensitive and 93% specific for neural-specific-antibodies. Responsive-to-immunotherapy-in-Epilepsy-and-Encephalopathy (RITE2) score ≥ 7 had 96% sensitivity and 86% specificity for favorable initial immunotherapy response. Application of these models may optimize autoantibody evaluations and immunotherapeutic trials.Entities:
Keywords: Autoimmune limbic encephalitis; Immunotherapy; Paraneoplastic limbic encephalitis; Predictive model
Mesh：
Substances：
Year: 2018 PMID： 30196836 DOI： 10.1016/j.jneuroim.2018.07.009
Source DB: PubMed Journal: J Neuroimmunol ISSN： 0165-5728 Impact factor: 3.478